Castle Biosciences Unveils Data Showing Pipeline Test Guides Personalized Atopic Dermatitis Treatment
Reuters
Oct 24, 2025
<a href="https://laohu8.com/S/CSTL">Castle Biosciences</a> Unveils Data Showing Pipeline Test Guides Personalized Atopic Dermatitis Treatment
Castle Biosciences Inc. announced new data from its clinical studies, set to be presented at the 25th Annual Fall Clinical Dermatology Conference taking place October 23-26, 2025. The company will present findings from a prospective, multicenter development and validation study of its pipeline atopic dermatitis $(AD)$ gene expression profile (GEP) test. Results demonstrate that the test can identify patients with a JAK inhibitor (JAKi) responder profile who are more likely to benefit from JAKi treatment compared to those receiving Th2-targeted therapy. The data suggest the test may help guide personalized treatment decisions in moderate-to-severe AD. Additionally, Castle Biosciences will present new analysis from 13,560 patients showing that its DecisionDx®-Melanoma test provides clinically relevant risk stratification across multiple histological subtypes of melanoma. This analysis confirms the clinical value of the test in offering prognostic information to inform risk-aligned management plans for melanoma patients.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9551401-en) on October 24, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.